These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 761206)

  • 1. Pharmacokinetics and disposition of 3-deazauridine in humans.
    Benvenuto JA; Hall SW; Farquhar D; Stewart DJ; Benjamin RS; Loo TL
    Cancer Res; 1979 Feb; 39(2 Pt 1):349-52. PubMed ID: 761206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Penetration of 3-deazauridine into human brain, intracerebral tumor, and cerebrospinal fluid.
    Stewart DJ; Benvenuto JA; Leavens M; Hall SW; Benjamin RS; Plunkett W; McCredie KB; Burgess MA; Loo TL
    Cancer Res; 1979 Oct; 39(10):4119-22. PubMed ID: 476649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity.
    Leyva A; van Groeningen CJ; Kraal I; Gall H; Peters GJ; Lankelma J; Pinedo HM
    Cancer Res; 1984 Dec; 44(12 Pt 1):5928-33. PubMed ID: 6498850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The disposition of 3-deazauridine in mice.
    Cysyk RL; Gormley PE; D'Anna ME; Adamson RH
    Drug Metab Dispos; 1978; 6(2):125-32. PubMed ID: 26526
    [No Abstract]   [Full Text] [Related]  

  • 5. High-pressure liquid chromatographic analysis of 3-deazauridine-5'-triphosphate in human cancer cells.
    Plunkett W; Benvenuto JA; Stewart DJ; Loo TL
    Cancer Treat Rep; 1979 Mar; 63(3):415-20. PubMed ID: 284846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I--II study of 3-deazauridine in adults with acute leukemia.
    Yap BS; McCredie KB; Keating MJ; Bodey GP; Freireich EJ
    Cancer Treat Rep; 1981; 65(5-6):521-4. PubMed ID: 7237473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo cellular kinetic and pharmacological studies of 1-beta-D-arabinofuranosylcytosine and 3-deazauridine chemotherapy for relapsing acute leukemia.
    Barlogie B; Plunkett W; Raber M; Latreille J; Keating M; McCredie K
    Cancer Res; 1981 Mar; 41(3):1227-35. PubMed ID: 7459863
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase I trial and pharmacokinetics of a daily x 5 schedule of 3-deazauridine.
    Creaven PJ; Priore RL; Mittelman A; Bruno S; Henderson ES; Rustum YM; Solomon JK
    Cancer Treat Rep; 1982 Jan; 66(1):81-4. PubMed ID: 7053271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetics of vinblastine by continuous intravenous infusion.
    Lu K; Yap HY; Loo TL
    Cancer Res; 1983 Mar; 43(3):1405-8. PubMed ID: 6825110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of N4-behenoyl-1-beta-D-arabinofuranosylcytosine in patients with acute leukemia.
    Ueda T; Nakamura T; Ando S; Kagawa D; Sasada M; Uchino H; Johno I; Akiyama Y
    Cancer Res; 1983 Jul; 43(7):3412-6. PubMed ID: 6850647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sample preparation and estimation of plasma concentration of 3-deazauridine by high-performance liquid chromatography.
    Lin KT; Momparler RL; Rivard GE
    Ther Drug Monit; 1983; 5(4):491-6. PubMed ID: 6659019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and pharmacokinetic studies of prolonged administration of high-dose uridine intended for rescue from 5-FU toxicity.
    van Groeningen CJ; Leyva A; Kraal I; Peters GJ; Pinedo HM
    Cancer Treat Rep; 1986 Jun; 70(6):745-50. PubMed ID: 3731137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological disposition of 1,4-bis (2-[(2-hydroxyethyl)amino]-ethylamino)-9,10-anthracenedione diacetate in the dog.
    Lu K; Loo TL
    Cancer Res; 1980 May; 40(5):1427-30. PubMed ID: 7370981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disposition and metabolism of finasteride in dogs.
    Carlin JR; Christofalo P; Arison BH; Ellsworth RE; Rosegay A; Miller RR; Chiu SH; VandenHeuvel WJ
    Drug Metab Dispos; 1997 Jan; 25(1):100-9. PubMed ID: 9010636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Orally active inhibitors of human leukocyte elastase. I. Disposition of L-683,845 in rats and rhesus monkeys.
    Vincent SH; Painter SK; Krieter PA; Colletti AE; Lyszack E; Rosegay A; Dean D; Luffer-Atlas D; Miller RR; Cioffe C; Chiu SH
    Drug Metab Dispos; 1996 Dec; 24(12):1369-77. PubMed ID: 8971144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transport of uridine and 3-deazauridine in cultured human lymphoblastoid cells.
    Dahlig-Harley E; Paterson AR; Robins MJ; Cass CE
    Cancer Res; 1984 Jan; 44(1):161-5. PubMed ID: 6580947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of cefroxadine after infusion to healthy volunteers.
    Cadórniga R; Molina IT; Pastoriza P; Negro S; Evora CM; Gutierrez JA
    Int J Clin Pharmacol Ther Toxicol; 1990 Oct; 28(10):435-9. PubMed ID: 2258253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of 3-deazauridine in the treatment of adults with solid tumors.
    Stewart DJ; McCredie KD; Barlogie B; Valdivieso M; Benjamin RS; Burgess MA; Bodey GP
    Cancer Treat Rep; 1980; 64(12):1295-9. PubMed ID: 7471119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice.
    Raynaud FI; Orr RM; Goddard PM; Lacey HA; Lancashire H; Judson IR; Beck T; Bryan B; Cotter FE
    J Pharmacol Exp Ther; 1997 Apr; 281(1):420-7. PubMed ID: 9103525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression.
    Geary RS; Leeds JM; Fitchett J; Burckin T; Truong L; Spainhour C; Creek M; Levin AA
    Drug Metab Dispos; 1997 Nov; 25(11):1272-81. PubMed ID: 9351904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.